Immunobiology and Molecular Characteristics of Peritoneal Exudate Cytotoxic T Lymphocytes (PEL), Their In Vivo IL-2-Dependent Blasts and IL-2-Independent Cytolytic Hybridomas

  • Gideon Berke
  • Dalia Rosen
  • Denise Ronen
  • Barbara Schick


Major histocompatibility complex (MHC)-restricted cytolytic T lymphocytes (CTL) are generated in response to allogeneic tissues (normal and malignant), tumors (autologous and syngeneic), viruses, and certain bacteria and self-antigens. CTL can be derived directly from spleen or lymph nodes after immunization, but these cells often require a secondary in vitro stimulation (Cerottini and Brunner. 1974). Peritoneal exudate CTL (PEL), collected during or shortly after a primary intraperitoneal (i.p.) immunization of rats and mice with allogeneic or irradiated syngeneic tumors, usually yield a highly potent, specific population of CTL (Berke et al., 1972a, 1972b, 1972c; Fishelson and Berke, 1978; Schick and Berke, 1977; Berke and Schick, 1980). Generation of PEL can be augmented by, but does not require, a secondary stimulation in vivo or in vitro.


Migration Chromium Lymphoma Leukemia Cysteine 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Amos DB (1960): Possible relations between the cytotoxic effects of isoantibody and host cell function. Ann NY Acad Sci 87: 273CrossRefGoogle Scholar
  2. Amos DB (1962): The use of simplified systems as an aid to the interpretation of mechanisms of graft rejection. Prog Allergy 6: 648Google Scholar
  3. Amos DB, Wakefield JD (1959): Growth of ascites tumor cells in diffusion chambers. II. Lysis and growth inhibition by diffusible isoantibody. J Natl Cancer Inst 22: 1077Google Scholar
  4. Andersson LC, Häyry P (1975): Clonal isolation of alloantigen-reactive T cells and characterization of their memory. Transplant Rev 25: 121Google Scholar
  5. Baker P, Weiser RS, Jutila J, Evans CA, Blandau RJ (1962): Mechanisms of tumor homograft rejection: The behavior of Sarcoma I ascites tumor in the A/Jax and C57BL/6K mouse. Ann NY Acad Sci 101: 46CrossRefGoogle Scholar
  6. Berke G (1980): Interaction of cytotoxic T lymphocytes and target cells Prog Allergy 27: 69–133Google Scholar
  7. Berke G (1989): Functions and mechanisms of lysis induced by cytotoxic T-lymphocytes and natural killer cells. In: Fundamental Immunol. Paul WE ed. Raven Press. pp 735–764Google Scholar
  8. Berke G (1993): Direct contact of cytotoxic T-lymphocyte receptors with target cell membrane determinants induces a prulytic rise of [CA’]i in the target that triggers disintegration. In this volume p. 194Google Scholar
  9. Berke G, Amos DB (1973): Mechanism of lymphocyte-mediated cytolysis: The LMC cycle and its role in transplantation immunity. Transplant Rev 17: 71–107Google Scholar
  10. Berke G, Rosen D (1987a): Are lytic granules, and perforin I thereof, involved in lysis induced by in vivo primed, peritoneal exudate CTL? Transplant Proc 19: 412–416Google Scholar
  11. Berke G, Rosen D (1987b): Circular lesions detected on membranes of target cells lysed by antibody and complement or natural killer (spleen) cells but not by in vivo primed cytolytic T lymphocytes. In: Membrane Mediated Cytotoxicity, Bonavida B, Collier RJ, eds. (UCLA Symposia, Park City), 1986, New York: Alan Liss, pp. 367–378Google Scholar
  12. Berke G, Rosen D (1988): Highly lytic in vivo primed CTL devoid of lytic granules and BLT-esterase activity acquire these constituents in the presence of T cell growth factors upon blast transformation in vivo. J Immunol 141: 1429–1436Google Scholar
  13. Berke G, Schick B (1980): Tumor immunity in the peritoneal cavity. Cont Top. Immunobiol. 10: 297–315 Berke G, Gabison D, Feldman M (1975): The frequency of effector cells in populations containing cytotoxic T lymphocytes. Eur J Immunol 5: 813–818CrossRefGoogle Scholar
  14. Berke G, Schick B (1980): Tumor immunity in the peritoneal cavity. Cont Top. Immunobiol. 10: 297–315 Berke G, Gabison D, Feldman M (1975): The frequency of effector cells in populations containing cytotoxic T lymphocytes. Eur J Immunol 5: 813–818CrossRefGoogle Scholar
  15. Berke G, Sullivan KA, Amos DB (1972b): Rejection of ascites tumor allograft. II. A pathway for cell-mediated tumor destruction in vitro by peritoneal exudate lymphoid cells. J Exp Med 136: 1594–1604CrossRefGoogle Scholar
  16. Berke G, Sullivan KA, Amos DB (1972c): Tumor immunity in vitro: Destruction of a mouse ascites tumor through a cycling pathway Science 177: 433–434Google Scholar
  17. Cerottini J-C, Brunner KT (1974): Cell-mediated cytotoxicity, allograft rejection and tumor immunity. Adv Immunol 18: 67CrossRefGoogle Scholar
  18. Denizot F, Brunet J-F, Roustan P, Harper K, Suzan M, Luciani M-F, Mattéi M-G, Golstein P (1989): Novel structures CTLA-2 alpha and CTLA-2 beta expressed in mouse activated T cells and mast cells and homologous to cysteine proteinase proregions. Eur J Immunol 19: 631–635CrossRefGoogle Scholar
  19. Denizot F, Wilson A, Battye F, Berke G, Shortman KGoogle Scholar
  20. ): Clonal expansion of T cells: A cytotoxic T cell response in vivo that involves precursor cell proliferation. Proc Natl Acad Sci USA 83: 6089–6092Google Scholar
  21. Dennert G, Anderson C, Prochazka G (1987): High activity of Nx-benzyloxycarbonyl-L-lysine thiobenzyl ester serine esterase and cytolytic perforin in cloned cell lines is not demonstrable in in-vivo-induced cytotoxic effector cells. Proc Nall Acad Sci USA 184: 5004–5008CrossRefGoogle Scholar
  22. Fishelson Z, Berke G (1978): T lymphocyte-mediated cytolysis: Dissociation of the binding from the lytic mechanism of the effector cells. J Immunol 120: 1121–1126Google Scholar
  23. Gorer D (1956): Some recent work on tumor immunity. Adv Cancer Res 4: 149CrossRefGoogle Scholar
  24. Hashimoto Y, Sudo H (1968): Studies on acquired transplantation resistance. III. Cytocidal effect of sensitized peritoneal lymphocytic cells of Donryu rats against the target Yoshida sarcoma cells in vitro. Gann 59: 7Google Scholar
  25. Hashimoto Y, Ishidate M, Takaku M (1965): Studies on acquired transplantation resistance. II. Action of peritoneal exudate cells of Donryu rats immune to the tumor against Yoshida sarcoma. Gann 56: 23Google Scholar
  26. Henkart PA (1985): Mechanisms of lymphocyte-mediated cytotoxicity. Ann Rev Immunol 3: 31CrossRefGoogle Scholar
  27. Herberman RB (1974): Cell-mediated immunity to tumor cells. Adv Cancer Res 19: 207CrossRefGoogle Scholar
  28. Hurt SN, Berke G, Clark WR (1979): A rapid method for generating cytotoxic effector cells in vivo. J Immunol Methods 28: 321–329CrossRefGoogle Scholar
  29. Kalina M, Berke G (1976): Contact regions of cytotoxic T lymphocyte-target cell conjugates. Cell Immunol 25: 41–51CrossRefGoogle Scholar
  30. Kaufmann Y, Berke G (1980): Enucleated cytotoxic T lymphocytes bind specifically to target cells in vitro. Transplantation 29: 374–378Google Scholar
  31. Kaufmann Y, Berke G (1981): Cell surface glycoproteins of cytotoxic T lymphocytes induced in vivo and in vitro. J Immunol 126: 1443–1446Google Scholar
  32. Kaufmann Y, Berke G (1983): Monoclonal cytotoxic T lymphocyte hybridoma capable of specific killing activity, antigenic responsiveness and inducible interleukin(s) secretion. J Immunol 131: 50–56Google Scholar
  33. Kaufmann Y, Berke G, Eshhar Z (1981a): Cytotoxic T lymphocyte hybridomas that mediate specific tumor cell lysis in vitro. Proc Natl Acad Sci USA 78: 2502–2506 Kaufmann Y, Berke G, Eshhar Z (1981b): Functional cytotoxic T lymphocyte hybridomas. Transplant Proc 13: 1170–1174Google Scholar
  34. Krähenbühl O, Tschopp J (1991): Perform-induced pore formation. Immunol Today 12: 399CrossRefGoogle Scholar
  35. Lotze MT, Finn OJ (1990): Recent advances in cellular immunology: Implications for immunity to cancer. Imm Today 11: 190CrossRefGoogle Scholar
  36. Martz E (1987): LFA-1 and other accessory molecules functioning in adhesions of T and B lymphocytes. Hum Immunol 18: 3CrossRefGoogle Scholar
  37. Moscovitch M, Kaufmann Y, Berke G (1984): Memory CTL-hybridoma: A model system to analyze the anamnestic response of CTL. J Immunol 133: 2369–2374Google Scholar
  38. Nagler-Anderson C, Allbritton NL, Verret CR, Eisen HN (1988): A comparison of the cytolytic properties of murine primary CD8+ cytotoxic T lymphocytes and cloned cytotoxic T cell lines. Immunol Rev 103: 111–125CrossRefGoogle Scholar
  39. Patt HM, Straube RL (1956): Measurement and nature of ascites tumor growth. Ann NY Acad Sci 63: 728CrossRefGoogle Scholar
  40. Podack ER, Hengartner H, Lichtenheld M (1991): A central role of perform in cytolysis? Ann Rev Immunol 9: 129CrossRefGoogle Scholar
  41. Schick B, Berke G (1977): Activity of tumor-associated lymphoid cells at short intervals after administration of irradiated syngeneic and allogeneic tumor cells. J Immunol 118: 986Google Scholar
  42. Straube RL, Hill MS, Patt HM (1955): Vascular permeability and ascites tumor growth. Proc Am Assoc Cancer Res 2: 49Google Scholar
  43. Wagner H, Röllinghoff M, Nossal GJV (1973): T cell-mediated immune responses induced in vitro: A probe of allograft and tumor immunity. Transplant Rev 17: 3Google Scholar
  44. Zagury D, Bernard J, Thierness N, Feldman M, Berke G (1975): Isolation and characterization of individual functionally reactive cytotoxic T lymphocytes: Conjugation, killing and recycling at the single cell level. Eur J Immunol 5: 818–822Google Scholar

Copyright information

© Birkhäuser Boston 1993

Authors and Affiliations

  • Gideon Berke
  • Dalia Rosen
  • Denise Ronen
  • Barbara Schick

There are no affiliations available

Personalised recommendations